TB-500 vs Semaglutide
Head-to-head comparison of TB-500 and Semaglutide for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Tb 500 | Semaglutide |
|---|---|---|
| Category | Healing & Recovery | Metabolic / GLP-1 Agonist |
| Mechanism | TB-500 works primarily through actin sequestration — it binds to G-actin monomers, preventing premature polymerization, which allows repair cells to migrate rapidly to injured areas. | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Veterinary use in some jurisdictions. Limited human RCTs completed. | FDA-approved (Ozempic for T2D, Wegovy for obesity) |
| Safety Profile | A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin-beta 4; No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike | Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient); Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness |
| Route | Subcutaneous | Subcutaneous (weekly injection); Oral tablet available (Rybelsus) |
| Dose Range | 500–1000 mcg/day SC (~5 mg/week average) | SC: 0.25–2.4 mg/week titrated over 16 weeks; Oral: 3–14 mg/day |
| Frequency | Once daily | Once weekly (SC); Once daily (oral) |
| Molecular Weight | ~889 g/mol | ~4113.6 g/mol |
| Half-Life | <2 hours plasma half-life; tissue effects persist 2–3 days | ~160–168 hours (~7 days) |
Overview
TB-500 and Semaglutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
TB-500 — Mechanism & Evidence
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing.
Key claims: Accelerates wound healing; Reduces inflammation; Promotes cardiac repair.
Semaglutide — Mechanism & Evidence
It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). There is no generic semaglutide available, and the FDA has warned about counterfeit products.
Key claims: Causes significant weight loss; Improves blood sugar control; Reduces cardiovascular risk.
Shared Research Applications
These peptides target different research areas. TB-500 focuses on Injury Recovery, Anti-Inflammatory, while Semaglutide targets Weight Management, Metabolic Health, Cardiovascular.
Safety Considerations
TB-500: A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin-beta 4 No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike Common anecdotal side effects: injection site pain/redness, lightheadedness, mild headache, nausea, fatigue
Semaglutide: Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient) Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness Serious but rare: pancreatitis, gallbladder disease, severe allergic reactions (hives, swelling, difficulty breathing)
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Semaglutide News: New Meta-Analysis Highlights Weight and Inflammatory Benefits
A recent systematic review and meta-analysis examines the effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. Early reports suggest meaningful reductions in body weight alongside improvements in inflammatory biomarkers, offering new context for peptide researchers and industry professionals.
Semaglutide News: How Long to Lose 30 Pounds on Semaglutide?
A common question in the semaglutide news cycle is how long it takes to lose 30 pounds on the medication. While individual results vary, clinical trial data and prescribing guidelines offer a general timeline. This article breaks down the expected weight loss trajectory and what factors influence the pace.
Semaglutide News 2026: How to Calculate Peptide Reconstitution
As semaglutide news 2026 continues to generate interest among researchers, understanding how to calculate reconstitution for peptides is essential. This guide covers the math, safety, and practical steps for accurate peptide preparation.